Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection

BACKGROUND: Diabetic macular edema (DME) is a leading cause of visual loss in diabetic patients and is managed using multiple anti-vascular endothelial growth factor (VEGF) agents such as bevacizumab, ranibizumab and aflibercept. The present study evaluates effectiveness of intravitreal injection of...

Descripción completa

Detalles Bibliográficos
Autores principales: Nawar, Amin E., Wasfy, Tamer, Shafik, Heba M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241277/
https://www.ncbi.nlm.nih.gov/pubmed/35768859
http://dx.doi.org/10.1186/s12886-022-02503-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241277/
https://www.ncbi.nlm.nih.gov/pubmed/35768859
http://dx.doi.org/10.1186/s12886-022-02503-x

Ejemplares similares